BWM
NBIX icon

BAM Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

BAM Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
2,598
+213
+9% +$31.6K 0.27% 103
2026
Q1 		$314K Buy
2,385
+42
+2% +$5.57K 0.24% 103
2025
Q4 		$332K Buy
2,343
+271
+13% +$39.3K 0.24% 98
2025
Q3 		$291K Buy
+2,072
New +$281K 0.23% 107

Other funds holding NBIX

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

BAM Wealth Management's NBIX Position: Q2 2026 in Review

BAM Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 8.9% in Q2 2026, buying an estimated $31.6K and bringing the position to 2,598 shares worth $438K. The position accounts for 0.27% of the portfolio, ranked #103.

BAM Wealth Management first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 350 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • BAM Wealth Management held 2,598 shares of Neurocrine Biosciences worth $438K as of Q2 2026.
  • BAM Wealth Management bought 213 Neurocrine Biosciences shares in Q2 2026, an estimated $31.6K.
  • Neurocrine Biosciences made up 0.27% of BAM Wealth Management's portfolio in Q2 2026, its #103 holding.
  • BAM Wealth Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 350 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on BAM Wealth Management's 13F filing for Q2 2026, filed 14 Jul 2026.